David Rolfe
Wedgewood Partners
David Rolfe UnitedHealth Group Incorporated stake
total: 97
Wedgewood Partners UNH trades
- Total transactions:
- 16
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 10
- Held since:
- 2021 Q3
- Held for:
- 15 quarters
- Latest activity:
- 2025 Q2
According to 2026 Q2 report, David Rolfe doesn't hold any UnitedHealth Group Incorporated (UNH) shares. To date, the estimated cost basis is nearly $434.91 for "buy" trades and estimated average "sell" price is $383.58. Wedgewood Partners first purchased UNH in 2021 Q3, initially acquiring 51,972 shares. Since the initial investment in UnitedHealth Group Incorporated (UNH), Wedgewood Partners has made 15 more transactions.
When did David Rolfe sell UnitedHealth Group Incorporated (UNH)?
David Rolfe sold off the entire UnitedHealth Group Incorporated (UNH) position in 2025 Q2.
When did David Rolfe buy UnitedHealth Group Incorporated (UNH)?
David Rolfe first invested in UnitedHealth Group Incorporated (UNH) in 2021 Q3 at the reported quarter-end price of $390.71 per share.
What's the cost basis of Wedgewood Partners's UNH stake?
The estimated cost basis for UnitedHealth Group Incorporated (UNH) stake is around $434.91 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $434.90
- Weighted AVG sell price:
- $383.58
David Rolfe's historical trades in UnitedHealth Group Incorporated
16 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q2
|
0.00%
|
0
|
$308.01
|
|
-100% (-10,302)
|
-0.64%
|
|
2025 Q1
|
0.64%
|
10,302
|
$308.01
|
$3,173,119
|
-81.40% (-45,082)
|
-2.73%
|
|
2024 Q4
|
5.52%
|
55,384
|
$505.86
|
$28,016,781
|
-4.57% (-2,651)
|
-0.24%
|
|
2024 Q3
|
6.38%
|
58,035
|
$605.87
|
$35,161,684
|
-1.50% (-885)
|
-0.11%
|
|
2024 Q2
|
6.80%
|
58,920
|
$565.29
|
$33,306,692
|
-2.11% (-1,273)
|
-0.14%
|
|
2024 Q1
|
6.23%
|
60,193
|
$517.55
|
$31,152,761
|
+22.28% (+10,969)
|
+1.14%
|
|
2023 Q4
|
5.35%
|
49,224
|
$516.85
|
$25,441,461
|
-1.89% (-947)
|
-0.12%
|
|
2023 Q3
|
6.05%
|
50,171
|
$504.19
|
$25,295,636
|
-31.66% (-23,246)
|
-1.89%
|
|
2023 Q2
|
5.69%
|
73,417
|
$480.62
|
$35,286,000
|
-2.41% (-1,811)
|
-0.15%
|
|
2023 Q1
|
6.03%
|
75,228
|
$472.58
|
$35,551,000
|
+24.09% (+14,606)
|
+1.17%
|
|
2022 Q4
|
5.90%
|
$530.17
|
-0.40% (-245)
|
|||
|
2022 Q3
|
5.78%
|
$505.04
|
-2.59% (-1,619)
|
|||
|
2022 Q2
|
5.54%
|
$513.62
|
-1.15% (-730)
|
|||
|
2022 Q1
|
4.55%
|
$509.97
|
+20.49% (+10,750)
|
|||
|
2021 Q4
|
3.50%
|
$502.13
|
+0.95% (+494)
|
|||
|
2021 Q3
|
2.86%
|
$390.71
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.